Key facts
- TRIO Pharmaceuticals’s last known valuation is $17.0M.
- It has raised $8.5M across 1 recorded rounds; the latest was Seed Round ($1.9M) in Nov 2022.
- Notable investors include CONNECT(San Diego), SeedFolio, Friedman BioVentures, Life Science Angels, Myeloma Investment Fund — 10 tracked in total.
- TRIO Pharmaceuticals has filed 2 Form Ds with the SEC, most recently Dec 2022 ($1.9M sold to 9 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for TRIO Pharmaceuticals
Funding rounds
1 roundsAbout TRIO Pharmaceuticals
Developer of a cancer immunotherapeutic antibody drug designed to generate immunogenic tumors. The company's drug offers dual-action tumor immunity-enhancing qualities aimed at treating cancers of high unmet medical needs by targeting specific antigens on the cancer cells and immunosuppressor cells, enabling physicians to improve efficacy, reduce toxicity, and increase treatment affordability.
- Sector
- Healthcare
- HQ
- San Francisco, CA, United States
- Founded
- 2018
- Employees
- 9
- Website
- triopharmaceuticals.com/
- Ownership
- Privately Held (backing)
TRIO Pharmaceuticals doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in TRIO Pharmaceuticals shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on TRIO Pharmaceuticals in its N-PORT filings yet. We sweep new filings monthly.